Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
Cancer Res., Jul;72(14):3457-62 (2012)
Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.
J. Clin. Endocrinol. Metab., Aug;97(8):2809-17 (2012)
Androgen action and metabolism in prostate cancer.
Mol. Cell. Endocrinol., Sep;360(1-2):3-13 (2012)
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
PLoS ONE., 7(1):e30062 (2012)
New hormonal therapies for castration-resistant prostate cancer.
Endocrinol. Metab. Clin. North Am., Sep;40(3):625-42, x (2011)
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cancer Res., Oct;71(20):6503-13 (2011)
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Clin. Cancer Res., Sep;17(18):5913-25 (2011)
Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.
Horm Cancer., Jun;2(3):145-56 (2011)
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.
Cancer Epidemiol. Biomarkers Prev., Apr;20(4):619-27 (2011)
Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.
J. Clin. Endocrinol. Metab., Feb;96(2):430-7 (2011)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.
J. Clin. Invest., Aug;120(8):2715-30 (2010)
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention.
Cancer Res., Feb;70(4):1286-95 (2010)
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.
Cancer Res., Dec;69(24):9448-56 (2009)
Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
Urol. Oncol., 27(3):251-7 (2009 May-Jun)
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion.
Nat Clin Pract Urol., Feb;6(2):76-85 (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Cancer Res., Jun;68(11):4447-54 (2008)
Prostate tissue androgens: history and current clinical relevance.
Urology., Aug;72(2):247-54 (2008)
Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications.
Best Pract. Res. Clin. Endocrinol. Metab., Apr;22(2):243-58 (2008)
Analysis of testosterone and dihydrotestosterone from biological fluids as the oxime derivatives using high-performance liquid chromatography/tandem mass spectrometry.
Rapid Commun. Mass Spectrom., 21(19):3200-6 (2007)
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Cancer Res., May;67(10):5033-41 (2007)
The basic biochemistry and molecular events of hormone therapy.
Curr Urol Rep., May;8(3):224-32 (2007)
Persistent intraprostatic androgen concentrations after medical castration in healthy men.
J. Clin. Endocrinol. Metab., Oct;91(10):3850-6 (2006)
Pulmonary surfactant proteins A and D directly suppress CD3+/CD4+ cell function: evidence for two shared mechanisms.
J. Immunol., Nov;169(10):5844-50 (2002)